Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma (NCT05597345)
Selinexor for the Treatment of Patients with Intermediate and High-Risk Smoldering Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.
Who can join: Review the eligibility criteria below.
Location: University of Rochester — Rochester, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Rochester — Rochester, New York
📞 Contact the Study Coordinator
Phone: (650) 504-2400
Email: jodi_lipof@urmc.rochester.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Smoldering Multiple Myeloma
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant — Tampa, Florida
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM — Boston, Massachusetts
- Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial — Salt Lake City, Utah
- Screening for AL Amyloidosis in Smoldering Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Smoldering Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.